FDA Approves J&J’s Spravato Nasal Spray as Standalone Treatment for Hard-to-Treat Depression
23 Jan 2025
The treatment landscape for major depressive disorder (MDD), particularly treatment-resistant depression, took a significant leap forward with the United States Food and Drug Administration (FDA) approving Spravato (esketamine) as a stand-alone therapy. This approval makes Spravato the first-ever standalone treatment for adults whose depression symptoms have shown inadequate response to...
Read More
